Bajaj Consumer Care

Mars Wrigley UK takes the precautionary step of recalling a limited number of Revels® 205g More to Share, Revels® 112g Pouch and Revels® 71g Treat Bag (price marked pack) in the UK

Retrieved on: 
Friday, December 1, 2023
Mars, Bajaj Consumer Care, Table tennis rubber, Heart

SLOUGH, England, Dec. 1, 2023 /PRNewswire/ -- Mars Wrigley UK is taking the precautionary step of recalling a limited number of Revels® 205g More To Share, Revels® 112g Pouch and Revels® 71g Treat Bag (price marked pack) in the UK with the specific best before date detailed below due to the potential presence of very small pieces of rubber.

Key Points: 
  • SLOUGH, England, Dec. 1, 2023 /PRNewswire/ -- Mars Wrigley UK is taking the precautionary step of recalling a limited number of Revels® 205g More To Share, Revels® 112g Pouch and Revels® 71g Treat Bag (price marked pack) in the UK with the specific best before date detailed below due to the potential presence of very small pieces of rubber.
  • No other Mars Wrigley brands, products, batch codes or best before dates are affected.
  • The precautionary recall in UK concerns only Revels® 205g More to Share, Revels® 112g Pouch and Revels® 71g Treat Bag (price marked pack) with the best before dates indicated below.
  • We sincerely apologise for any inconvenience caused.

Silicone Market is Anticipated To Reach USD 16760 Million By 2029, Witnessing A CAGR of 3.3% | Valuates Reports

Retrieved on: 
Wednesday, May 3, 2023
Linearity, Silicone, Urbanization, Plastic, Semiconductor, Food, Aluminium, Toxicity, Steel, Type, USD, Computer, Sterilization, Houston, Tablet, Écu, Silicon, Bajaj Consumer Care, LED, ICT, Application, Elastomer, Polychlorinated biphenyl, Growth, Fungal infection, Weather, Transport, Silicone rubber, Glass, Synthetic rubber, Road, Electronics, Gel

The global Silicone market was valued at USD 12930 million in 2022 and is anticipated to reach USD 16760 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.

Key Points: 
  • The global Silicone market was valued at USD 12930 million in 2022 and is anticipated to reach USD 16760 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.
  • The silicone market is primarily driven by silicone's superior characteristics and strong demand in the electronics sector.
  • Furthermore, the increasing adoption of silicon in the healthcare industry is expected to fuel the silicone market.
  • During the forecast period, the silicone market in the Asia Pacific is anticipated to exhibit the greatest CAGR.

Silicone Market is Anticipated To Reach USD 16760 Million By 2029, Witnessing A CAGR of 3.3% | Valuates Reports

Retrieved on: 
Wednesday, May 3, 2023
Linearity, Silicone, Urbanization, Plastic, Semiconductor, Food, Aluminium, Toxicity, Steel, Type, USD, Computer, Sterilization, Houston, Tablet, Écu, Silicon, Bajaj Consumer Care, LED, ICT, Application, Elastomer, Polychlorinated biphenyl, Growth, Fungal infection, Weather, Transport, Silicone rubber, Glass, Synthetic rubber, Road, Electronics, Gel

The global Silicone market was valued at USD 12930 million in 2022 and is anticipated to reach USD 16760 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.

Key Points: 
  • The global Silicone market was valued at USD 12930 million in 2022 and is anticipated to reach USD 16760 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.
  • The silicone market is primarily driven by silicone's superior characteristics and strong demand in the electronics sector.
  • Furthermore, the increasing adoption of silicon in the healthcare industry is expected to fuel the silicone market.
  • During the forecast period, the silicone market in the Asia Pacific is anticipated to exhibit the greatest CAGR.

Mallinckrodt Announces Appointment of Karen Ling to Its Board of Directors

Retrieved on: 
Wednesday, August 17, 2022
Expansion, U.S. Securities and Exchange Commission, Wyeth, Senior, Analgesic, Autoimmunity, Private Securities Litigation Reform Act, SEC, Leadership, Bajaj Consumer Care, Board, Ajman Specialty General Hospital, Annual report, The Company, American International Group, Financial compensation, Boston University, Patient, The Jed Foundation, Company, Acquisition, Human resources, Neurology, Allergan, AIG, Risk, Nephrology, Company secretary, Immunotherapy, Board of directors, Professional Football Compensation Committee, Rheumatology, Yale University, Ophthalmology, The, Economics, Organization, Management, Medicine, Merck, Mallinckrodt

DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Karen Ling has been appointed to the Company's Board of Directors, effective August 12, 2022.

Key Points: 
  • DUBLIN, Aug. 17, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Karen Ling has been appointed to the Company's Board of Directors, effective August 12, 2022.
  • With the addition of Ms. Ling, the Mallinckrodt Board will expand to eight directors, seven of whom are independent.
  • "We are thrilled to welcome a leader of Karen's caliber to the Mallinckrodt Board," said Paul Bisaro, Chairman of the Mallinckrodt Board of Directors.
  • "I have great admiration for the work Mallinckrodt does to serve patients, and I am honored to join Mallinckrodt at such an important time for the Company," said Ms. Ling.

Lysando AG Strengthens Board of Directors by Appointment of Mr. Sang Jung Kim

Retrieved on: 
Tuesday, July 12, 2022
Health, Medical Devices, Hospitals, Research, Science, Pharmaceutical, Biotechnology, Medical device, Business development, Biotechnology, Agricultural chemistry, Novozymes, Multimedia, Bajaj Consumer Care, R, Seoul National University, Marketing, Bacteria, Enzyme, Director, Armageddon, National university, Board of directors, Board, Partnership, Management, Fine chemical, Antibiotics, Food

The market-leader for antimicrobial proteins, Lysando AG, has appointed Sang Jung Kim as new member to the Board of Directors.

Key Points: 
  • The market-leader for antimicrobial proteins, Lysando AG, has appointed Sang Jung Kim as new member to the Board of Directors.
  • As Director of Sales & Marketing at AMICOGEN, a leading manufacturer of technical enzymes and strategic partner to the Lysando AG, he is already familiar to Lysando.
  • Sang Jung Kim and AMICOGEN share our entrepreneurial spirit and goal to prevent the antibiotic Armageddeon," says the Chairman of the Board of Lysando AG, Count Markus Matuschka de Greiffenclau.
  • The Board of Directors officially added Sang Jung Kim on 1st February 2022.

CLEAN HANDS ON THE GO: MYKIREI BY KAO® LAUNCHES MOBILE HAND WASHING UNIT

Retrieved on: 
Tuesday, June 14, 2022
Foam, Seed, KMS, Program, Curriculum, School, Goldwell, Wash, KAO, Conditioner, Powell v. Home Depot USA, Inc., Multimedia, KAOI, Panther Bior, Social media, Bajaj Consumer Care, Water, Kao, Hand, Footprint, Kao Corporation, Cosmetics, Marketing, Jergens

NEW YORK, June 14, 2022 /PRNewswire/ -- From June 16 - 18, 2022, people of New York City will be able to experience the TikTok-famous MyKirei by KAO soaps first-hand. Via a MyKirei by KAO Wash & Go sink-equipped mobile unit targeting hygiene hot spots like dog parks and playgrounds, the groundbreaking personal care brand brings its popular Yuzu Flower and Paw Print™ Foam Hand Washes straight to the masses. The exact whereabouts of the Wash & Go experience will be posted on the MyKirei by KAO Instagram, @mykirei.

Key Points: 
  • Via aMyKirei by KAO Wash & Gosink-equipped mobile unit targeting hygiene hot spots like dog parks and playgrounds, the groundbreaking personal care brand brings its popular Yuzu Flower and Paw Print Foam Hand Washes straight to the masses.
  • The exact whereabouts of the Wash & Go experience will be posted on the MyKirei by KAO Instagram, @mykirei .
  • "The mobile hand washing unit is a unique, impactful way for MyKirei by KAO to better acquaint consumers with the superior quality of our biodegradable, earth and skin-friendly Foam Hand Washes," says Heather Warnke, Senior Director of Marketing, Consumer Care, A/EMEA at Kao.
  • "Encouraging hand washing has been a Kao initiative since 2009, and we are always looking for new and innovative ways to instill good hygiene."

Galderma to Present New Findings From Innovative Product Portfolio at the 2022 VCS Annual Symposium

Retrieved on: 
Wednesday, June 8, 2022
Science, Other Science, Biotechnology, Research, Surgery, Health, FDA, Clinical Trials, Blood, Wound, Inflammation, Pain, PLLA, Allergy, Toxin (comics), Vascular occlusion, Skin infection, Herbal, Muscle, History, Galderma, Hypertrophic scar, Tenderness, Human, Infection, Headache, Vitamin, Partnership, Bleeding, Myasthenia gravis, Red, Rash, Bajaj Consumer Care, Dermatology, Pimple, Sculptra, Catherine Disher, Infarction, Nausea, Bruise, Lip, Patient, ALS, Muscle weakness, Skin, Cyst, Skin discoloration, Use, Research, Nose, Medication, Amyotrophic lateral sclerosis, Upper respiratory tract infection, FDA, Risk, Face, Safety, Eyebrow, Death, Pharmaceutical industry, Cosmetics, Canning, Birth control, Dietary supplement, Medicine, Aesthetics, EU, Botulinum toxin, Ipsen

Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.

Key Points: 
  • Galderma is the worlds largest independent dermatology company, present in approximately 100 countries.
  • We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine.
  • Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes.
  • Because we understand that the skin were in shapes our life stories, we are advancing dermatology for every skin story.

Galderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea

Retrieved on: 
Thursday, June 2, 2022
Cream, Life, Itch, Press release, Pharmacy, Food, Blemish, Week, Edema, Partnership, Pain, Patient satisfaction, BPO, Red, FDA, Patient, Rosacea, Compliance, MD, Bajaj Consumer Care, Benzoyl peroxide, General manager, Erythema, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dermatology, Swelling, Pharmaceutical industry, Cosmetics, Health insurance, Aesthetics, Galderma

FORT WORTH, Texas, June 2, 2022  /PRNewswire/ -- Galderma announced today the availability of EPSOLAY (benzoyl peroxide) Cream, 5% in the U.S. following approval by the U.S. Food and Drug Administration (FDA) on April 22, 2022. EPSOLAY Cream is the first and only microencapsulated benzoyl peroxide (E-BPO) topical treatment proven to relieve the bumps and blemishes of rosacea and provides rapid, significant and sustained relief.1,2 [a]

Key Points: 
  • "EPSOLAY Cream represents an important advancement for those who are living with this incredibly challenging skin condition."
  • "EPSOLAY Cream showed great efficacy and tolerability in the pivotal trials, as evidenced by high patient satisfaction and compliance."
  • A month's supply of EPSOLAY Cream costs as little as $0 for commercially covered patients with the Galderma CAREConnect savings card at participating pharmacies.
  • Because we understand that the skin we're in shapes our life stories, we are advancing dermatology for every skin story.

Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®

Retrieved on: 
Thursday, April 14, 2022
Cream, Annual general meeting, U.S. Securities and Exchange Commission, COVID-19, Security (finance), NASDAQ, Research, Psoriasis, GLOBE, Patient, Review, MPR, Silicon dioxide, Forward-looking statement, Parent, Acne, FDA, Sol–gel process, Tretinoin, Dermatology, Skin, Annual report, Food, Private Securities Litigation Reform Act, Doctor of Philosophy, OTC, Pharmacy, Company, Publication, Interview, Partnership, Allure, Bajaj Consumer Care, Marketing, Vii, Ix, Intellectual property, Beauty, Depression, SEC, History, Rosacea, Coronavirus, Industry, BPO, NESS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Terminology, Retirement, American Academy, Risk, Benzoyl peroxide, Pharmaceutical industry, Birth control, Cosmetics, Explosive, Galderma, Aesthetics

TWYNEO Cream was approved by the U.S. Food and Drug Administration on July 27, 2021 and is being commercialized in the U.S. by Galderma.

Key Points: 
  • TWYNEO Cream was approved by the U.S. Food and Drug Administration on July 27, 2021 and is being commercialized in the U.S. by Galderma.
  • TWYNEO uses Sol-Gels patented microencapsulation technology which allows these two ingredients to be combined and enables their controlled release.
  • TWYNEO Cream is now available at all major pharmacy chains throughout the U.S. by prescription.
  • TWYNEO is the first acne treatment that contains a fixeddose combination of benzoyl peroxide and tretinoin.

Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA

Retrieved on: 
Friday, March 25, 2022
Tretinoin, Private Securities Litigation Reform Act, Risk, Company, Face, Bajaj Consumer Care, Partnership, Skin, Neck, Marketing, Silicon dioxide, Forward-looking statement, Retirement, Coronavirus, Human, Benzoyl peroxide, Rosacea, SEC, Research, Doctor of Philosophy, History, Psoriasis, U.S. Securities and Exchange Commission, Vii, American Academy of Dermatology, Quality of life, Industry, Comedo, Ix, COVID-19, Intellectual property, American Academy, NDA, Acne, PDUFA, Terminology, FDA, Annual report, Patient, Disease, Security (finance), Pharmaceutical industry, Aesthetics, Galderma, Dermatology

Acne vulgaris is a common multifactorial skin disease that according to the American Academy of Dermatology affects up to 50 million people in the U.S.

Key Points: 
  • Acne vulgaris is a common multifactorial skin disease that according to the American Academy of Dermatology affects up to 50 million people in the U.S.
  • Acne vulgaris can have a profound effect on the quality of life of those suffering from the disease.
  • Because we understand that the skin were in shapes our life stories, we are advancing dermatology for every skin story.
  • Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.